Risk factors for Candida tropicalis fungemia in patients with cancer

Clinical Infectious Diseases

Volumn 33, Issue 10, 2001, Pages 1676-1681

  Kontoyiannis, D P ^a   Vaziri, I ^a   Hanna, H A ^a   Boktour, M ^a   Thornby, J ^a   Hachem, R ^a   Bodey, G P ^a   Raad, I I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CULTURE; CANCER PATIENT; CANDIDA ALBICANS; CANDIDA TROPICALIS; CANDIDIASIS; CATHETER INFECTION; CHILD; DRUG RESPONSE; FEMALE; FUNGEMIA; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; LENGTH OF STAY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CHILD; FEMALE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0035889586     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/323812     Document Type: Article

References (29)

1. Importance of Candida species other than C. albicans as pathogens in oncology patients
2. Hematogenous and major organ candidiasis
3. Candida tropicalis: A major pathogen in immunocompromised patients
4. The epidemiology of hematogenous candidiasis caused by different Candida species
5. Candidemia in cancer patients: A prospective, multi-center surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
6. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients
7. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome
8. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
9. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
10. The value of fungal surveillance cultures as predictors of systemic fungal infections
11. The pathogenesis of Candida tropicalis infections in mice
12. Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice
13. Gastrointestinal colonization and systemic dissemination by C. albicans and C. tropicalis in intact and immunocompromised mice
14. Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice
15. Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis
16. Predictors of adverse outcome in cancer patients with candidemia
17. Fluconazole versus amphotericin B for the management of candidemia in adults: A meta-analysis
18. Risk factors and predictors of outcome in cancer patients with breakthrough candidemia
19. Fatal Candida tropicalis fungemia in a leukemic patient receiving fluconazole prophylaxis
20. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis
21. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750
22. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
23. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada
24. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
25. Candida krusei fungemia
26. The contribution of fluconazole to the changing epidemiology of invasive candidal infections
27. Candidal meningitis in children with cancer
28. Fungemia in patients with leukemia
29. Therapeutic approaches in patients with candidemia: Evaluation of multicenter, prospective, observational study